Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 10 |
| List of Tables | 8 | 3 |
| List of Figures | 11 | 3 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Region - Introduction | 14 | 2 |
| GBI Research Report Guidance | 15 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Region - Market Overview | 16 | 4 |
| Production Cycle for the Seasonal Influenza Vaccines | 16 | 1 |
| The Asia-Pacific Region Seasonal Influenza Vaccine Market | 16 | 1 |
| Revenue for the Seasonal Influenza Vaccine Market | 17 | 2 |
| Geographical Segmentation | 19 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Region - Geographical Landscape | 20 | 80 |
| Australia | 20 | 1 |
| Vaccination Pattern | 20 | 1 |
| Population | 20 | 1 |
| Vaccinated Population Contribution | 21 | 2 |
| Vaccination Coverage | 23 | 1 |
| Number of Doses per Person | 23 | 1 |
| Number of Total Doses | 23 | 2 |
| Doses Contribution | 25 | 1 |
| Number of Public and Private Doses | 25 | 1 |
| Cost of Vaccine | 25 | 1 |
| Total Revenue | 26 | 2 |
| New Zealand | 28 | 1 |
| Vaccination Pattern | 28 | 1 |
| Population | 28 | 1 |
| Vaccinated Population Contribution | 29 | 2 |
| Vaccination Coverage | 31 | 1 |
| Number of Doses per Person | 31 | 1 |
| Number of Total Doses | 31 | 2 |
| Doses Contribution | 33 | 1 |
| Number of Public and Private Doses | 33 | 1 |
| Cost of Vaccine | 33 | 1 |
| Total Revenue | 34 | 2 |
| Major Players by Market Share | 36 | 1 |
| Taiwan | 37 | 1 |
| Vaccination Pattern | 37 | 1 |
| Population | 37 | 1 |
| Vaccinated Population Contribution | 38 | 1 |
| Vaccination Coverage | 39 | 1 |
| Number of Doses per Person | 39 | 1 |
| Number of Total Doses | 39 | 2 |
| Doses Contribution | 41 | 1 |
| Number of Public and Private Doses | 41 | 1 |
| Cost of Vaccine | 41 | 1 |
| Total Revenue | 42 | 2 |
| Major Players by Market Share | 44 | 1 |
| Philippines | 45 | 1 |
| Vaccination Pattern | 45 | 1 |
| Population | 45 | 1 |
| Vaccinated Population Contribution | 46 | 1 |
| Vaccination Coverage | 47 | 1 |
| Number of Doses per Person | 47 | 1 |
| Number of Total Doses | 47 | 2 |
| Doses Contribution | 49 | 1 |
| Number of Public and Private Doses | 49 | 1 |
| Cost of Vaccine | 49 | 1 |
| Total Revenue | 50 | 2 |
| Major Players by Market Share | 52 | 1 |
| Malaysia | 53 | 1 |
| Vaccination Pattern | 53 | 1 |
| Population | 53 | 1 |
| Vaccinated Population Contribution | 54 | 1 |
| Vaccination Coverage | 55 | 1 |
| Number of Doses per Person | 55 | 1 |
| Number of Total Doses | 55 | 1 |
| Doses Contribution | 56 | 1 |
| Number of Public and Private Doses | 57 | 1 |
| Cost of Vaccine | 57 | 1 |
| Total Revenue | 58 | 2 |
| Major Players by Market Share | 60 | 1 |
| Hong Kong | 61 | 1 |
| Vaccination Pattern | 61 | 1 |
| Population | 61 | 1 |
| Vaccinated Population Contribution | 62 | 1 |
| Vaccination Coverage | 63 | 1 |
| Number of Doses per Person | 63 | 1 |
| Number of Total Doses | 63 | 1 |
| Doses Contribution | 64 | 1 |
| Number of Doses Public and Private | 65 | 1 |
| Cost of Vaccine | 65 | 1 |
| Total Revenue | 66 | 2 |
| Major Players by Market Share | 68 | 1 |
| Singapore | 69 | 1 |
| Vaccination Pattern | 69 | 1 |
| Population | 69 | 1 |
| Vaccinated Population Contribution | 70 | 1 |
| Vaccination Coverage | 71 | 1 |
| Number of Doses per Person | 71 | 1 |
| Number of Total Doses | 71 | 1 |
| Doses Contribution | 72 | 1 |
| Number of Doses Public and Private | 73 | 1 |
| Cost of Vaccine | 73 | 1 |
| Total Revenue | 74 | 2 |
| Major Players by Market Share | 76 | 1 |
| Japan | 77 | 1 |
| Vaccination Pattern | 77 | 1 |
| Population | 77 | 1 |
| Vaccinated Population Contribution | 78 | 1 |
| Vaccination Coverage | 79 | 1 |
| Number of Doses per Person | 79 | 1 |
| Number of Total Doses | 79 | 2 |
| Cost of Vaccine | 81 | 1 |
| Total Revenue | 82 | 1 |
| Major Players in the Market | 83 | 1 |
| China | 84 | 1 |
| Vaccination Pattern | 84 | 1 |
| Population | 84 | 1 |
| Vaccinated Population Contribution | 85 | 1 |
| Vaccination Coverage | 86 | 1 |
| Number of Doses per Person | 86 | 1 |
| Number of Total Doses | 86 | 2 |
| Doses Contribution | 88 | 1 |
| Cost of Vaccine | 88 | 1 |
| Total Revenue | 89 | 2 |
| Major Players in the Market | 91 | 1 |
| India | 92 | 1 |
| Vaccination Pattern | 92 | 1 |
| Population | 92 | 1 |
| Vaccinated Population Contribution | 93 | 1 |
| Vaccination Coverage | 94 | 1 |
| Number of Doses per Person | 94 | 1 |
| Number of Total Doses | 94 | 2 |
| Doses Contribution | 96 | 1 |
| Cost of Vaccine | 96 | 1 |
| Total Revenue | 97 | 2 |
| Major Players in the Market | 99 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Region - Drivers and Restraints | 100 | 12 |
| Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region | 100 | 1 |
| Threat of Pandemic Influenza | 100 | 1 |
| Increasing Vaccination Coverage for Seasonal Influenza Vaccines | 101 | 3 |
| Emergence of Novel Production Technologies and Vaccines | 104 | 1 |
| Population Growth | 105 | 1 |
| Economic Reasons | 105 | 1 |
| Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region | 105 | 1 |
| Entry Barriers in the Seasonal Influenza Vaccine Market | 105 | 1 |
| Variable Demand | 106 | 1 |
| Limited Production Capacity | 106 | 1 |
| Australia | 106 | 1 |
| Drivers | 106 | 1 |
| Government Support for Immunization against Seasonal Influenza | 106 | 1 |
| Restraints | 106 | 1 |
| Keeping Seasonal Influenza Vaccines Out of PBS | 106 | 1 |
| Incidences of Adverse Reaction after Vaccination | 106 | 1 |
| New Zealand | 107 | 1 |
| Drivers | 107 | 1 |
| Increasing Vaccination Coverage | 107 | 1 |
| Government Support for Immunization | 107 | 1 |
| Low Price for the Vaccine | 107 | 1 |
| Restraints | 107 | 1 |
| Low Vaccination Coverage for Influenza in Children | 107 | 1 |
| Taiwan | 107 | 1 |
| Drivers | 107 | 1 |
| Growth in Elderly Population | 107 | 1 |
| Government Support for Immunization | 107 | 1 |
| Low Price of Vaccine | 107 | 1 |
| Restraints | 107 | 1 |
| Stagnating Vaccination Coverage | 107 | 1 |
| Philippines | 108 | 1 |
| Drivers | 108 | 1 |
| Population Growth | 108 | 1 |
| Rapid Increase in Vaccination Coverage | 108 | 1 |
| Restraints | 108 | 1 |
| Low Contribution from the Government | 108 | 1 |
| High Price of Vaccine | 108 | 1 |
| Malaysia | 108 | 1 |
| Drivers | 108 | 1 |
| Rapidly Increasing Vaccination Coverage | 108 | 1 |
| Restraints | 108 | 1 |
| Low Contribution from the Government | 108 | 1 |
| Low Overall Coverage | 108 | 1 |
| High Price of Vaccine | 109 | 1 |
| Hong Kong | 109 | 1 |
| Drivers | 109 | 1 |
| Low Price of Seasonal Influenza Vaccine | 109 | 1 |
| Government Programs for Seasonal Influenza Vaccination | 109 | 1 |
| Rise in the Cost of Vaccine | 109 | 1 |
| Restraints | 109 | 1 |
| Low Contribution from the Government | 109 | 1 |
| Singapore | 109 | 1 |
| Drivers | 109 | 1 |
| Rapidly Increasing Vaccination Coverage | 109 | 1 |
| Increase in Elderly Population | 110 | 1 |
| Restraints | 110 | 1 |
| Low Contribution from the Government | 110 | 1 |
| Japan | 110 | 1 |
| Drivers | 110 | 1 |
| Influenza Immunization Program | 110 | 1 |
| Incidences of Pandemic Influenza | 110 | 1 |
| Rapidly Growing Elderly Population | 110 | 1 |
| Subsidized Immunization for the Elderly | 110 | 1 |
| Restraints | 110 | 1 |
| Non-reimbursement of Influenza Vaccination Costs | 110 | 1 |
| Limited Availability Period for Subsidized Vaccines | 110 | 1 |
| Absence of Scientific Studies Establishing Safety and Efficacy of Flu Vaccines in Japan | 110 | 1 |
| Differential Pricing Among Prefectures | 111 | 1 |
| China | 111 | 1 |
| Drivers | 111 | 1 |
| High Awareness about Flu Due to Pandemic Influenza | 111 | 1 |
| Availability of Low-cost Flu Vaccines in China | 111 | 1 |
| Restraints | 111 | 1 |
| Absence of a National Influenza Vaccination Program | 111 | 1 |
| Lack of Manufacturing Capacity | 111 | 1 |
| Absence of Reimbursement on Seasonal Influenza Vaccination | 111 | 1 |
| India | 111 | 1 |
| Drivers | 111 | 1 |
| Increasing Awareness about Seasonal Influenza | 111 | 1 |
| Positive Prospects of Availability of a Low-cost Vaccine in Future | 111 | 1 |
| Restraints | 111 | 1 |
| Low Vaccination Coverage for Seasonal Influenza | 111 | 1 |
| Absence of a National Influenza Vaccination Program | 111 | 1 |
| Absence of Low-cost Domestic Manufacturers of Seasonal influenza Vaccines in India | 111 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Region - Regulatory Landscape | 112 | 18 |
| Registration Process and Regulations in Australia | 112 | 2 |
| Registration Process and Regulations in New Zealand | 114 | 3 |
| Registration Process and Regulations in Taiwan | 117 | 1 |
| Registration Process and Regulations in the Philippines | 118 | 2 |
| Registration Process and Regulations in Malaysia | 120 | 2 |
| Registration Process and Regulations in Hong Kong | 122 | 1 |
| Registration Process and Regulations in Singapore | 123 | 1 |
| Registration Process and Regulations in Japan | 124 | 2 |
| Registration Process and Regulations in China | 126 | 2 |
| Registration Process and Regulations in India | 128 | 2 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Region - Pipeline Analysis | 130 | 8 |
| Seasonal Influenza Vaccines - Promising Vaccines under Clinical Development | 130 | 1 |
| Profiles for Promising Vaccines under Clinical Development | 131 | 1 |
| Optaflu | 131 | 1 |
| Overview | 131 | 1 |
| Efficacy | 131 | 1 |
| Safety | 131 | 1 |
| Clinical Study Details | 131 | 1 |
| GSK2186877A | 131 | 1 |
| Overview | 131 | 1 |
| Efficacy | 131 | 1 |
| Safety | 132 | 1 |
| Clinical Study Details | 132 | 1 |
| Intanza / Flu-ID | 132 | 1 |
| Overview | 132 | 1 |
| Efficacy | 132 | 1 |
| Safety | 132 | 1 |
| Clinical Study Details | 132 | 1 |
| Fluad Pediatric | 133 | 1 |
| Overview | 133 | 1 |
| Efficacy | 133 | 1 |
| Safety | 133 | 1 |
| Clinical Study Details | 133 | 1 |
| FluBlok | 133 | 1 |
| Overview | 133 | 1 |
| Research and Development Pipeline | 134 | 4 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Region - Competitive Landscape | 138 | 4 |
| Major Seasonal Influenza Vaccines Marketed in the APAC Region | 138 | 1 |